{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:56:12Z","timestamp":1790740572771,"version":"4.1.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Early-phase oncology clinical trials are often underrepresented in studies regarding publication of trial results. This study investigated the publication status of early-phase clinical trials, focusing on trials of compounds discontinued in clinical development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two retrospective cohorts were formed: one included early-phase trials supporting European Medicines Agency marketing authorization applications (2017-2020), while the second cohort included early-phase trials of discontinued compounds. Trials were matched with database registry and their corresponding publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The first cohort consisted of 73 trials. Nine ongoing trials were excluded. No full publication or full report was found for 11% (n\u2009=\u20097\/64) of trials. Median time from registered closure date to publication of trial results as full publication or full report was 109\u2009days (IQR \u2212733 to 597). Trials sponsored by large-size firms (HR 2.25 [95% CI, 1.23-4.1]), with &amp;gt;100 patients (HR 2.15 [95% CI, 1.19-3.88]) and duration &amp;gt;2\u2009years (HR 6.83 [95% CI, 3.03-14.38]) were more likely to be published. The cohort with discontinued compounds consisted of 66 clinical trials. After exclusion of 9 ongoing trials, 39% (n\u2009=\u200922\/57) lacked full publication or full report. Median time from registered closure date to publication of trial results as full publication or full report was 693 days (IQR 406\u2013963). No covariates influencing publication status were found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Timely and complete publication of early-phase clinical trial results remains inadequate. Forty percent of trials with discontinued drugs are not publicly reported, and even among approved compounds, 11% of early-phase trial results cannot be found in the public domain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag361","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:47:17Z","timestamp":1789213637000},"source":"Crossref","is-referenced-by-count":0,"title":["The insufficient publication of early-phase clinical trials in oncology"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4007-9449","authenticated-orcid":false,"given":"Merel J J","family":"Lucassen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Netherlands Cancer Institute , Amsterdam, 1066 CX,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4096-0917","authenticated-orcid":false,"given":"Tim","family":"Schutte","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Netherlands Cancer Institute , Amsterdam, 1066 CX,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-4639","authenticated-orcid":false,"given":"Alwin D R","family":"Huitema","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute , Amsterdam, 1066 CX,","place":["The Netherlands"]},{"name":"Department of Pharmacology, Princess M\u00e1xima Center for Pediatric Oncology , Utrecht, 3584 CS,","place":["The Netherlands"]},{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University , Utrecht, 3584 CX,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-2279","authenticated-orcid":false,"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Netherlands Cancer Institute , Amsterdam, 1066 CX,","place":["The Netherlands"]},{"name":"Department of Medical Oncology, University Medical Center Utrecht, Utrecht University , Utrecht, 3584 CX,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"2026092923064579200_oyag361-B1","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"2026092923064579200_oyag361-B2","author":"Regulation (EU)","year":"2014"},{"key":"2026092923064579200_oyag361-B3","author":"Code of Federal Regulations","year":"2024"},{"key":"2026092923064579200_oyag361-B4","author":"The Medicines for Human Use (Clinical Trials) Regulations 2025","year":"2025"},{"key":"2026092923064579200_oyag361-B5","author":"ClinicalTrials.gov [Internet]","year":"2000"},{"key":"2026092923064579200_oyag361-B6","author":"Clinical Trials Information System (CTIS)"},{"key":"2026092923064579200_oyag361-B7","author":"International Clinical Trials Registry Platform (ICTRP)"},{"key":"2026092923064579200_oyag361-B8","doi-asserted-by":"publisher","first-page":"e081660","DOI":"10.1136\/bmj-2024-081660","article-title":"SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials","volume":"389","author":"Hr\u00f3bjartsson","year":"2025","journal-title":"BMJ"},{"key":"2026092923064579200_oyag361-B9","author":"International Council for Harmonisation of Technical Requirements for Pharmacueticals for Human Use (IHC) Expert Working Group","year":"2025"},{"key":"2026092923064579200_oyag361-B10","doi-asserted-by":"publisher","first-page":"e759","DOI":"10.1016\/S2214-109X(24)00514-X","article-title":"Reporting summary results in clinical trial registries: updated guidance from WHO","volume":"13","author":"Chan","year":"2025","journal-title":"Lancet Glob Health"},{"key":"2026092923064579200_oyag361-B11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/bmjebm-2022-111967","article-title":"Responsible dissemination of health and medical research: some guidance points","volume":"28","author":"Ravinetto","year":"2023","journal-title":"BMJ Evid Based Med"},{"key":"2026092923064579200_oyag361-B12","doi-asserted-by":"publisher","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"key":"2026092923064579200_oyag361-B13","doi-asserted-by":"publisher","first-page":"f6104","DOI":"10.1136\/bmj.f6104","article-title":"Non-publication of large randomized clinical trials: cross sectional analysis","volume":"347","author":"Jones","year":"2013","journal-title":"BMJ"},{"key":"2026092923064579200_oyag361-B14","doi-asserted-by":"publisher","first-page":"e068981","DOI":"10.1136\/bmjopen-2022-068981","article-title":"Clinical study reports published by the European Medicines Agency 2016-2018: a cross-sectional analysis","volume":"13","author":"Byrne","year":"2023","journal-title":"BMJ Open"},{"key":"2026092923064579200_oyag361-B15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy","volume":"358","author":"Turner","year":"2008","journal-title":"N Engl J Med"},{"key":"2026092923064579200_oyag361-B16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13063-017-2068-3","article-title":"Association of the FDA Amendment Act with trial registration, publication, and outcome reporting","volume":"18","author":"Phillips","year":"2017","journal-title":"Trials"},{"key":"2026092923064579200_oyag361-B17","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1186\/s12885-019-6232-x","article-title":"Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation","volume":"19","author":"Omae","year":"2019","journal-title":"BMC Cancer"},{"key":"2026092923064579200_oyag361-B18","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1001\/jamainternmed.2016.6008","article-title":"Failure of investigational drugs in Late-Stage clinical development and publication of trial results","volume":"176","author":"Hwang","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2026092923064579200_oyag361-B19","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10637-017-0549-6","article-title":"Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database","volume":"36","author":"Shepshelovich","year":"2018","journal-title":"Invest New Drugs"},{"key":"2026092923064579200_oyag361-B20","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/j.respe.2022.03.069","article-title":"Publication bias and reporting bias with a focus on dose-escalation trials of protein kinase inhibitors developed in oncology","volume":"70","author":"Caquelin","year":"2022","journal-title":"Revue d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"},{"key":"2026092923064579200_oyag361-B21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/onco.13759","article-title":"Publication bias in gastrointestinal oncology trials performed over the past decade","volume":"26","author":"Peters","year":"2021","journal-title":"Oncologist"},{"key":"2026092923064579200_oyag361-B22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1634\/theoncologist.2015-0516","article-title":"Assessing the eventual publication of clinical trial abstracts submitted to a large annual oncology meeting","volume":"21","author":"Massey","year":"2016","journal-title":"Oncologist"},{"key":"2026092923064579200_oyag361-B23","doi-asserted-by":"publisher","first-page":"k3218","DOI":"10.1136\/bmj.k3218","article-title":"Compliance with requirement to report results on the EU clinical trials register: cohort study and web resource","volume":"362","author":"Goldacre","year":"2018","journal-title":"BMJ"},{"key":"2026092923064579200_oyag361-B24","author":"European Medicines Agency","year":"2019"},{"key":"2026092923064579200_oyag361-B25","doi-asserted-by":"publisher","first-page":"e000738","DOI":"10.1136\/bmjmed-2023-000738","article-title":"Availability of results of clinical trials registered on EU Clinical Trials Register: cross sectional audit study","volume":"3","author":"DeVito","year":"2024","journal-title":"BMJ Med"},{"key":"2026092923064579200_oyag361-B26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0140-6736(19)33220-9","article-title":"Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study","volume":"395","author":"DeVito","year":"2020","journal-title":"Lancet"},{"key":"2026092923064579200_oyag361-B27","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamainternmed.2018.0263","article-title":"Results reporting for trials with the same sponsor, drug, and condition in ClinicalTrials.gov and peer-reviewed publications","volume":"178","author":"Fain","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2026092923064579200_oyag361-B28","doi-asserted-by":"publisher","first-page":"e849","DOI":"10.1093\/oncolo\/oyac156","article-title":"Availability of results of trials studying pancreatic adenocarcinoma over the past 10 years","volume":"27","author":"Pellat","year":"2022","journal-title":"Oncologist"},{"key":"2026092923064579200_oyag361-B29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/M13-0480","article-title":"Reporting discrepancies between the ClinicalTrials.gov results database and peer-reviewed publications","volume":"160","author":"Hartung","year":"2014","journal-title":"Ann Intern Med"},{"key":"2026092923064579200_oyag361-B30","doi-asserted-by":"publisher","first-page":"e031138","DOI":"10.1136\/bmjopen-2019-031138","article-title":"Selective reporting bias in randomised controlled trials from two network meta-analyses: comparison of clinical trial registrations and their respective publications","volume":"9","author":"Wong","year":"2019","journal-title":"BMJ Open"},{"key":"2026092923064579200_oyag361-B31","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMsr1611785","article-title":"Trial reporting in ClinicalTrials.gov\u2014the final rule","volume":"375","author":"Zarin","year":"2016","journal-title":"N Engl J Med"},{"key":"2026092923064579200_oyag361-B32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","article-title":"Trends in clinical success rates and therapeutic focus","volume":"18","author":"Dowden","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026092923064579200_oyag361-B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-39609-x","article-title":"Success rates of American clinical oncology trials by geographic factors","volume":"16","author":"Patiyal","year":"2026","journal-title":"Sci Rep"},{"key":"2026092923064579200_oyag361-B34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"2026092923064579200_oyag361-B35","author":"European Medicines Agency","year":"2017"},{"key":"2026092923064579200_oyag361-B36","author":"European Medicines Agency","year":"2020"},{"key":"2026092923064579200_oyag361-B37","author":"European Medicines Agency","year":"2019"},{"key":"2026092923064579200_oyag361-B38","author":"European Medicines Agency","year":"2018"},{"key":"2026092923064579200_oyag361-B39","author":"Clarivate"},{"key":"2026092923064579200_oyag361-B40","doi-asserted-by":"publisher","first-page":"e1508","DOI":"10.1002\/onco.13810","article-title":"Phase I trial of cemiplimab, radiotherapy, cyclophosphamide, and granulocyte macrophage colony-stimulating factor in patients with recurrent or metastatic head and neck squamous cell carcinoma","volume":"26","author":"Babiker","year":"2021","journal-title":"Oncologist"},{"key":"2026092923064579200_oyag361-B41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.lungcan.2021.02.034","article-title":"Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): data from the phase 1 NSCLC expansion cohort","volume":"155","author":"Moreno","year":"2021","journal-title":"Lung Cancer"},{"key":"2026092923064579200_oyag361-B42","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ygyno.2020.08.026","article-title":"PD-1 blockade in recurrent or metastatic cervical cancer: data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer","volume":"159","author":"Rischin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2026092923064579200_oyag361-B43","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"2026092923064579200_oyag361-B44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40425-016-0176-3","article-title":"Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810","volume":"4","author":"Falchook","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2026092923064579200_oyag361-B45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1200\/JCO.2016.34.15_suppl.101","article-title":"A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors","volume":"34","author":"Infante","year":"2016","journal-title":"JCO"},{"key":"2026092923064579200_oyag361-B46","doi-asserted-by":"publisher","first-page":"11006","DOI":"10.1200\/jco.2015.33.15_suppl.11006","article-title":"Safety and activity of DCR-MYC, a first-in-class dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors","volume":"33","author":"Tolcher","year":"2015","journal-title":"JCO"},{"key":"2026092923064579200_oyag361-B47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/thy.2021.0565","article-title":"Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","journal-title":"Thyroid"},{"key":"2026092923064579200_oyag361-B48","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/sj.bjc.6602423","article-title":"Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy","volume":"92","author":"Nurgat","year":"2005","journal-title":"Br J Cancer"},{"key":"2026092923064579200_oyag361-B49","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/archinte.168.12.1294","article-title":"Why patients continue to participate in clinical research","volume":"168","author":"Wendler","year":"2008","journal-title":"Arch Intern Med"},{"key":"2026092923064579200_oyag361-B50","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1200\/JCO.2006.06.0269","article-title":"Patients\u2019 decision-making process regarding participation in phase I oncology research","volume":"24","author":"Agrawal","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026092923064579200_oyag361-B51","doi-asserted-by":"publisher","first-page":"Mr000011","DOI":"10.1002\/14651858.MR000011.pub3","article-title":"Time to publication for results of clinical trials","volume":"11","author":"Showell","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026092923064579200_oyag361-B52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00467-022-05553-x","article-title":"Missing trial results: analysis of the current publication rate of studies in pediatric dialysis from 2003 to 2020","volume":"38","author":"Patry","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"2026092923064579200_oyag361-B53","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jama.290.4.495","article-title":"Factors associated with failure to publish large randomized trials presented at an oncology meeting","volume":"290","author":"Krzyzanowska","year":"2003","journal-title":"JAMA"},{"key":"2026092923064579200_oyag361-B54","doi-asserted-by":"publisher","first-page":"oyaf042","DOI":"10.1093\/oncolo\/oyaf042","article-title":"Barriers to publishing early phase clinical trials: the oncologists\u2019 perspective","volume":"30","author":"Lucassen","year":"2025","journal-title":"Oncologist"},{"key":"2026092923064579200_oyag361-B55","doi-asserted-by":"publisher","first-page":"e110418","DOI":"10.1371\/journal.pone.0110418","article-title":"Why are medical and health-related studies not being published? A systematic review of reasons given by investigators","volume":"9","author":"Song","year":"2014","journal-title":"PLoS One"},{"key":"2026092923064579200_oyag361-B56","author":"Thomas","year":"2021"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag361\/71046466\/oyag361.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag361\/71046466\/oyag361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag361\/71046466\/oyag361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:06:56Z","timestamp":1790737616000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag361\/8792930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag361","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,9]]},"article-number":"oyag361"}}